The system
Medicare Part D premiums to jump 50% in 2027
Average monthly premiums for Medicare Part D prescription drug plans are projected to rise from $34 to $51 next year.
Latest Medical Research news
Clinical trials
Combination therapy achieves high major pathological response in pMMR colon cancer
The UNICORN phase 2 trial shows neoadjuvant botensilimab plus balstilimab produced a 36% major pathological response in pMMR colon cancer and 100% in dMMR disease, with 100% 12-month event-free survival in both combination cohorts.
Clinical trials
Flagship Pioneering launches AI drug discovery company Etcelera
Flagship Pioneering merged three AI biotech startups into a new company, Etcelera, on October 29, 2026. The firm, led by Adrian Rawcliffe, combines AI with perturbation data to predict clinical trial success for drugs targeting hematology, metabolism, and immunology.
Regulation
FDA Panel Vote Lifts Restrictions on Six Unapproved Peptides
An FDA advisory panel narrowly voted to recommend lifting restrictions on six unapproved peptides, leading HHS to announce it will not enforce against compounders making them, a move that expands access but raises significant safety concerns.
The system
Measles outbreak in Pennsylvania Amish communities
A major measles outbreak in Pennsylvania, concentrated in Lancaster County's Amish communities, has resulted in over 1,350 cases and five deaths.
Explore topics
Monitored sourcesBioPharma Dive, kff.orgNature Medicine, targetedonc.comBioPharma Dive, pharmaphorum.comBioPharma Dive, nbcnews.comMedPage Today, ksat.comNature Medicine, oncodaily.comfda.gov, hcplive.com
The index
Regulation
Early-Onset Colorectal Cancer Tumors Show Distinct Cellular Composition
A new single-nucleus RNA sequencing atlas reveals that colorectal cancers in younger patients have a higher proportion of stromal cells and lower proportion of epithelial cells compared to tumors in older individuals. This fundamental difference in the tumor microenvironment, validated across large external cohorts, is linked to specific molecular subtypes and signaling pathways.
Regulation
FDA Approves Voceryq for Recurrent Respiratory Papillomatosis
The FDA has granted accelerated approval to Voceryq, the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV.
The system
Setara Biosciences launches with $90 million for rare disease drug
A new biotech company, Setara Biosciences, has launched with $90 million to develop a therapy for Charcot-Marie-Tooth disease and overactive bladder, continuing the work of Actio Biosciences after its acquisition by Jazz Pharmaceuticals.
Clinical trials
PET-Guided Strategy Enables Chemotherapy De-Escalation in HER2-Positive Breast Cancer
Long-term data from the phase II PHERGain trial shows a PET-guided, response-adapted strategy allowed many patients with HER2-positive early breast cancer to safely omit chemotherapy while maintaining a five-year invasive disease-free survival rate of 89.5%.
Regulation
U.S. bans imports from three Chinese genomics firms
The U.S. Department of Homeland Security has banned imports from BGI Group, BGI Genomics, and MGI Tech, alleging ties to forced labor and genetic surveillance in China's Xinjiang region.
Evidence
Industrial Water Pollution Linked to Higher PSP Risk
A 25-year U.K. study finds living near industrial facilities that pollute water with heavy metals and pesticides significantly increases the risk of developing progressive supranuclear palsy, a rare neurodegenerative disease.
Clinical trials
Artiva Biotherapeutics halts AlloNK trial and cuts 94% of staff after patient deaths
Artiva Biotherapeutics is ending development of its AlloNK cell therapy and laying off most employees after two patient deaths in a Phase 2a trial, one linked to chemotherapy neurotoxicity.
Evidence
Novo Nordisk lawsuit fails to halt Lilly obesity drug ads
A federal judge denied Novo Nordisk's request to block Eli Lilly's advertising campaign comparing weight-loss drugs Wegovy and Zepbound, finding no evidence of irreparable harm.
Clinical trials
MDT-BRIDGE trial shows 74.6% resection rate with neoadjuvant durvalumab
A phase 2 trial of neoadjuvant durvalumab plus chemotherapy in resectable and borderline resectable NSCLC achieved a 74.6% overall resection rate.
Clinical trials
BioNTech's trastuzumab pamirtecan shows modest PFS benefit in HER2-low breast cancer
A Phase 3 trial for BioNTech and DualityBio's antibody-drug conjugate trastuzumab pamirtecan met its primary endpoint, delaying tumor progression in HER2-low metastatic breast cancer, though safety concerns and immature survival data temper its impact.
Profiles
Data and guides
Also filed
The system
Star Therapeutics secures $200 million to refocus pipeline
Star Therapeutics announced a $200 million venture capital financing round on October 23, 2026, to advance its rare disease biologics pipeline following the sale of its Vega Therapeutics subsidiary.
Research areas
Christina Applegate's MS Misdiagnosis Highlights Diagnostic Advances
Christina Applegate's five-year misdiagnosis of multiple sclerosis shows persistent challenges in neurology, even as modern tools like the McDonald Criteria and central vein sign imaging accelerate accurate diagnosis.
Clinical trials
FDA Launches Neuroscience Nexus to Accelerate Alzheimer's Prevention
The FDA has created the Neuroscience Advancement and Innovation Nexus, a new agency-wide program to coordinate regulatory science for brain conditions, with an initial focus on accelerating Alzheimer's prevention trials.
Clinical trials
Camupepimut vaccine shows benefit in pancreatic cancer subgroup
The AMPLIFY-7P phase 2 trial found camupepimut did not improve disease-free survival overall but showed significant benefit in ctDNA-negative pancreatic cancer patients.
Regulation
Intismeran-Keytruda combo cuts melanoma recurrence risk by 42%
A Phase 3 trial shows Moderna's intismeran vaccine combined with Merck's Keytruda reduces the risk of recurrence or death in high-risk melanoma patients by 42% versus Keytruda alone, with regulatory approval possible by 2027.
Clinical trials
ADHD Drugs Show Promise for Menopausal Brain Fog in Early Trials
A scoping review finds ADHD medications lisdexamfetamine and atomoxetine significantly improved self-reported executive function in perimenopausal women, though objective cognitive test scores did not change. Researchers highlight the need for larger trials to confirm efficacy and safety for this unapproved use.
Regulation
GSK and Ionis win first FDA approval for hepatitis B functional cure
The FDA has approved GSK and Ionis's RNA-based drug Hibsago, offering a functional cure for chronic hepatitis B in adults without cirrhosis after a six-month treatment course.
Evidence
FDA issues final guidance on prescription drug companion app labeling
The FDA has released final guidance clarifying when software used alongside prescription drugs must be included in a drug's official label and submitted for agency review, establishing a clear regulatory pathway.
Clinical trials
Merck KGaA acquires Silence Therapeutics for $1.3 billion
Merck KGaA is buying Silence Therapeutics for $1.3 billion to gain control of divesiran, an RNAi therapy showing positive Phase 2 results in polycythemia vera.
The system
Estuary Biotherapeutics Launches with $93M for ADPKD Gene Therapies
Estuary Biotherapeutics launched with $93 million in Series A funding to develop one-time gene therapies for autosomal dominant polycystic kidney disease.
The system
Arrowhead's ARO-MAPT shows major tau reduction in early trial
Arrowhead Pharmaceuticals' RNAi drug ARO-MAPT reduced tau protein by an average of 73% in healthy volunteers, demonstrating significant target engagement via subcutaneous dosing.
Regulation
FDA expands Anktiva approval for BCG-unresponsive bladder cancer
The FDA has expanded approval of nogapendekin alfa inbakicept-pmln (Anktiva) with BCG to treat adults with BCG-unresponsive, high-grade papillary-only non-muscle invasive bladder cancer.
Browse sections
Common questions
What is Bench to Bed for?
Reporting studies and trials as evidence: what was actually tested, in whom, and what it showed. Research areas groups the science, Clinical trials follows the pipeline, Regulation covers approvals, Evidence deals with how strong a finding is, and The system covers funding and publication.
Does a study reported here mean a treatment works?
No. Most published findings are early, small or in animals, and the piece says which. Nothing on this site is medical advice, and no reader should change anything about their treatment because of a summary.
How do you handle preprints and press releases?
They are reported as what they are. A piece names whether its source was a peer-reviewed paper, a preprint, a conference abstract or an institutional release, and links to it, because the type of source changes how much weight it carries.
Is the writing done by a person?
Nobody is bylined and nobody is presented as a researcher or a physician. Pieces are written with automated assistance from the source material, crediting the publication or journal instead, as Sources and methods explains.
How do I flag a factual error?
The Corrections page asks for the article address and the specific claim you believe is wrong. Corrections are made on the article with a dated note at the foot, and substantive ones are listed.
Can I subscribe by RSS?
Yes, at /feed.xml, carrying every piece as it publishes. It needs no account and no key.